Department of Surgery, Lewis Katz School of Medicine, Temple University Hospital, Philadelphia, PA.
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
J Am Coll Surg. 2021 Apr;232(4):470-480.e2. doi: 10.1016/j.jamcollsurg.2020.11.020. Epub 2020 Dec 18.
The albumin-bilirubin score (ALBI) has recently been shown to have increased accuracy in predicting post-hepatectomy liver failure and mortality compared with the Model for End-Stage Liver Disease (MELD). However, the use of ALBI as a predictor of postoperative mortality for other surgical procedures has not been analyzed. The aim of this study was to measure the predictive power of ALBI compared with MELD-sodium (MELD-Na) across a wide range of surgical procedures.
Patients undergoing cardiac, pulmonary, esophageal, gastric, gallbladder, pancreatic, splenic, appendix, colorectal, adrenal, renal, hernia, and aortic operations were identified in the 2015-2018 American College of Surgeons NSQIP database. Patients with missing laboratory data were excluded. Univariable analysis and receiver operator characteristic curves were performed for 30-day mortality and morbidity. Areas under the curves were calculated to validate and compare the predictive abilities of ALBI and MELD-Na.
Of 258,658 patients, the distribution of ALBI grades 1, 2, 3 were 51%, 42%, and 7%, respectively. Median MELD-Na was 7.50 (interquartile range 6.43 to 9.43). Overall 30-day mortality rate was 2.7% and overall morbidity was 28.6%. Increasing ALBI grade was significantly associated with mortality (ALBI grade 2: odds ratio [OR] 5.24; p < 0.001; ALBI grade 3: OR 25.6; p < 0.001) and morbidity (ALBI grade 2: OR 2.15; p < 0.001; ALBI grade 3: OR 6.12; p < 0.001). On receiver operator characteristic analysis, ALBI outperformed MELD-Na with increased accuracy in several operations.
ALBI score predicts mortality and morbidity across a wide spectrum of surgical procedures. When compared with MELD-Na, ALBI more accurately predicts outcomes in patients undergoing pulmonary, elective colorectal, and adrenal operations.
白蛋白-胆红素评分(ALBI)最近被证明在预测肝切除术后肝衰竭和死亡率方面比终末期肝病模型(MELD)更准确。然而,ALBI 作为其他手术术后死亡率预测因子的应用尚未得到分析。本研究旨在比较 ALBI 与 MELD-钠(MELD-Na)在广泛的手术中的预测能力。
在美国外科医师学会 NSQIP 数据库中确定了 2015 年至 2018 年期间接受心脏、肺、食管、胃、胆囊、胰腺、脾、阑尾、结直肠、肾上腺、肾、疝和主动脉手术的患者。排除了实验室数据缺失的患者。进行了单变量分析和受试者工作特征曲线分析,以评估 30 天死亡率和发病率。计算曲线下面积以验证和比较 ALBI 和 MELD-Na 的预测能力。
在 258658 名患者中,ALBI 分级 1、2、3 的分布分别为 51%、42%和 7%。中位 MELD-Na 为 7.50(四分位距 6.43 至 9.43)。总 30 天死亡率为 2.7%,总发病率为 28.6%。ALBI 分级的升高与死亡率显著相关(ALBI 分级 2:比值比[OR] 5.24;p < 0.001;ALBI 分级 3:OR 25.6;p < 0.001)和发病率(ALBI 分级 2:OR 2.15;p < 0.001;ALBI 分级 3:OR 6.12;p < 0.001)。在受试者工作特征分析中,ALBI 在几个手术中表现出比 MELD-Na 更高的准确性。
ALBI 评分可预测广泛手术的死亡率和发病率。与 MELD-Na 相比,ALBI 更准确地预测了肺、择期结直肠和肾上腺手术患者的结局。